PRIMENENIE KOMBINIROVANNYKh ORAL'NYKh KONTRATsEPTIVOV, SODERZhAShchIKh DROSPIRENON, PRI LEChENII SINDROMA POLIKISTOZNYKh YaIChNIKOV

A. A Raykova

V.F.Snegirev Archives of Obstetrics and Gynecology ›› 2016, Vol. 3 ›› Issue (4) : 214 -215.

PDF
V.F.Snegirev Archives of Obstetrics and Gynecology ›› 2016, Vol. 3 ›› Issue (4) : 214 -215. DOI: 10.17816/aog35393
Original study articles
oration

PRIMENENIE KOMBINIROVANNYKh ORAL'NYKh KONTRATsEPTIVOV, SODERZhAShchIKh DROSPIRENON, PRI LEChENII SINDROMA POLIKISTOZNYKh YaIChNIKOV

Author information +
History +
PDF

Abstract

Polycystic ovary syndrome is one of the most studied pathologies in gynecology, but the etiology and pathogenesis has not been fully elucidated. An important role in the treatment of combined oral contraceptives play a latest-generation progestogen, such as drospirenone. The use of combined oral contraceptives with antiandrogen activity justified pathogenetically.

Cite this article

Download citation ▾
A. A Raykova. PRIMENENIE KOMBINIROVANNYKh ORAL'NYKh KONTRATsEPTIVOV, SODERZhAShchIKh DROSPIRENON, PRI LEChENII SINDROMA POLIKISTOZNYKh YaIChNIKOV. V.F.Snegirev Archives of Obstetrics and Gynecology, 2016, 3(4): 214-215 DOI:10.17816/aog35393

登录浏览全文

4963

注册一个新账户 忘记密码

References

RIGHTS & PERMISSIONS

Eco-Vector

AI Summary AI Mindmap
PDF

61

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/